Intravitreal aflibercept for the treatment of previously treated exudative age related macular degeneration

Trial Profile

Intravitreal aflibercept for the treatment of previously treated exudative age related macular degeneration

Not yet recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Aflibercept (Primary) ; Vascular endothelial growth factor A inhibitors
  • Indications Wet macular degeneration
  • Focus Therapeutic Use
  • Acronyms AAA Study
  • Sponsors Bayer
  • Most Recent Events

    • 17 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top